Laura E. Johnson
Immunology and Microbiology · University of Michigan
Publications
96
Citations
2,533
Est. group size
—
Recurring co-author estimate
Active years
38
Publishing since 1989
Typically publishes in teams of ~8 · 14% small-team papers (≤3 authors) · across 20 venues
- Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer
Journal for ImmunoTherapy of Cancer · 2026
- Investigating eating architecture and the impact of the precision of recorded eating time: a cross-sectional study
American Journal of Clinical Nutrition · 2025
- Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer
Human Vaccines & Immunotherapeutics · 2024
- Estimating the prevalence of potential and actionable drug‐gene interactions in Irish primary care: A cross‐sectional study
British Journal of Clinical Pharmacology · 2024
- Estimating the prevalence of potential and actionable drug-gene interactions in Irish primary care: a cross-sectional study
2024
- 806 Anti-tumor efficacy of ADT in combination with AR targeted therapies and anti-PD-1 is limited by regulatory T cells in murine prostate models
Regular and Young Investigator Award Abstracts · 2024
- 1478 Phase 1/2 trial of androgen deprivation, with or without pTVG-AR, and with or without nivolumab, in patients with newly diagnosed, high-risk prostate cancer
2024
- Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer
Journal for ImmunoTherapy of Cancer · 2023
- Supplementary Figure Legends, Table Legend from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
2023
- Supplementary Figures 1 - 4, Table 1 from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
2023
- Supplementary Figure Legends, Table Legend from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
2023
- Supplementary Figures 1 - 4, Table 1 from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
2023
- Data from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
2023
- Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Journal for ImmunoTherapy of Cancer · 2022
- The experience of patients at high risk of difficult peripheral intravenous cannulation: An Australian prospective observational study
Australasian Emergency Care · 2021
- Journal for ImmunoTherapy of Cancer×5
- Journal of Clinical Oncology×3
- Regular and Young Investigator Award Abstracts×3
- Australasian Emergency Care×2
- American Journal of Infection Control×2
- Robert C. Chick
Immunology and Microbiology · The Ohio State University
- Shurong Zhou
Immunology and Microbiology · University of Michigan
- Mohamed Dit Mady Traore
Immunology and Microbiology · University of Michigan
- Aki Hoji
Immunology and Microbiology · Indiana University
- Jasdeep S. Kler
Immunology and Microbiology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile